nodes	percent_of_prediction	percent_of_DWPC	metapath
Vorinostat—HDAC4—urinary bladder cancer	0.47	0.656	CbGaD
Vorinostat—NCOR1—urinary bladder cancer	0.247	0.344	CbGaD
Vorinostat—HDAC6—prostate gland—urinary bladder cancer	0.00341	0.0514	CbGeAlD
Vorinostat—HDAC8—prostate gland—urinary bladder cancer	0.00303	0.0456	CbGeAlD
Vorinostat—HDAC4—prostate gland—urinary bladder cancer	0.00294	0.0443	CbGeAlD
Vorinostat—HDAC11—prostate gland—urinary bladder cancer	0.00264	0.0398	CbGeAlD
Vorinostat—NCOR1—prostate gland—urinary bladder cancer	0.00256	0.0386	CbGeAlD
Vorinostat—HDAC3—prostate gland—urinary bladder cancer	0.00224	0.0338	CbGeAlD
Vorinostat—HDAC8—renal system—urinary bladder cancer	0.00206	0.0311	CbGeAlD
Vorinostat—HDAC1—prostate gland—urinary bladder cancer	0.00206	0.031	CbGeAlD
Vorinostat—HDAC9—prostate gland—urinary bladder cancer	0.00202	0.0305	CbGeAlD
Vorinostat—HDAC3—seminal vesicle—urinary bladder cancer	0.0019	0.0286	CbGeAlD
Vorinostat—HDAC6—female reproductive system—urinary bladder cancer	0.00186	0.0281	CbGeAlD
Vorinostat—HDAC11—renal system—urinary bladder cancer	0.0018	0.0271	CbGeAlD
Vorinostat—NCOR1—renal system—urinary bladder cancer	0.00175	0.0263	CbGeAlD
Vorinostat—HDAC1—seminal vesicle—urinary bladder cancer	0.00174	0.0262	CbGeAlD
Vorinostat—HDAC8—female reproductive system—urinary bladder cancer	0.00165	0.0249	CbGeAlD
Vorinostat—HDAC4—female reproductive system—urinary bladder cancer	0.00161	0.0242	CbGeAlD
Vorinostat—HDAC1—epithelium—urinary bladder cancer	0.00151	0.0228	CbGeAlD
Vorinostat—HDAC3—urethra—urinary bladder cancer	0.0015	0.0226	CbGeAlD
Vorinostat—HDAC8—vagina—urinary bladder cancer	0.00149	0.0225	CbGeAlD
Vorinostat—HDAC1—smooth muscle tissue—urinary bladder cancer	0.00146	0.0219	CbGeAlD
Vorinostat—HDAC11—female reproductive system—urinary bladder cancer	0.00144	0.0217	CbGeAlD
Vorinostat—HDAC1—renal system—urinary bladder cancer	0.0014	0.0211	CbGeAlD
Vorinostat—NCOR1—female reproductive system—urinary bladder cancer	0.0014	0.0211	CbGeAlD
Vorinostat—HDAC1—urethra—urinary bladder cancer	0.00138	0.0207	CbGeAlD
Vorinostat—NR0B1—female reproductive system—urinary bladder cancer	0.00131	0.0198	CbGeAlD
Vorinostat—HDAC11—vagina—urinary bladder cancer	0.0013	0.0196	CbGeAlD
Vorinostat—HDAC2—Teniposide—Etoposide—urinary bladder cancer	0.00129	1	CbGdCrCtD
Vorinostat—HDAC3—female reproductive system—urinary bladder cancer	0.00123	0.0185	CbGeAlD
Vorinostat—HDAC1—female reproductive system—urinary bladder cancer	0.00112	0.0169	CbGeAlD
Vorinostat—HDAC3—vagina—urinary bladder cancer	0.00111	0.0167	CbGeAlD
Vorinostat—HDAC9—female reproductive system—urinary bladder cancer	0.0011	0.0166	CbGeAlD
Vorinostat—HDAC6—lymph node—urinary bladder cancer	0.00109	0.0164	CbGeAlD
Vorinostat—HDAC2—prostate gland—urinary bladder cancer	0.00103	0.0156	CbGeAlD
Vorinostat—HDAC1—vagina—urinary bladder cancer	0.00101	0.0153	CbGeAlD
Vorinostat—HDAC8—lymph node—urinary bladder cancer	0.000966	0.0146	CbGeAlD
Vorinostat—HDAC4—lymph node—urinary bladder cancer	0.000939	0.0142	CbGeAlD
Vorinostat—HDAC11—lymph node—urinary bladder cancer	0.000843	0.0127	CbGeAlD
Vorinostat—NCOR1—lymph node—urinary bladder cancer	0.000818	0.0123	CbGeAlD
Vorinostat—HDAC2—epithelium—urinary bladder cancer	0.00076	0.0114	CbGeAlD
Vorinostat—HDAC2—smooth muscle tissue—urinary bladder cancer	0.000732	0.011	CbGeAlD
Vorinostat—HDAC3—lymph node—urinary bladder cancer	0.000717	0.0108	CbGeAlD
Vorinostat—HDAC2—renal system—urinary bladder cancer	0.000705	0.0106	CbGeAlD
Vorinostat—HDAC1—lymph node—urinary bladder cancer	0.000656	0.00989	CbGeAlD
Vorinostat—HDAC9—lymph node—urinary bladder cancer	0.000646	0.00973	CbGeAlD
Vorinostat—HDAC2—female reproductive system—urinary bladder cancer	0.000564	0.0085	CbGeAlD
Vorinostat—HDAC2—vagina—urinary bladder cancer	0.00051	0.00769	CbGeAlD
Vorinostat—HDAC2—lymph node—urinary bladder cancer	0.00033	0.00497	CbGeAlD
Vorinostat—Decreased appetite—Mitomycin—urinary bladder cancer	0.000301	0.00441	CcSEcCtD
Vorinostat—Lethargy—Fluorouracil—urinary bladder cancer	0.000299	0.00438	CcSEcCtD
Vorinostat—Nausea—Valrubicin—urinary bladder cancer	0.000299	0.00437	CcSEcCtD
Vorinostat—Fatigue—Mitomycin—urinary bladder cancer	0.000299	0.00437	CcSEcCtD
Vorinostat—Serum creatinine increased—Doxorubicin—urinary bladder cancer	0.000296	0.00433	CcSEcCtD
Vorinostat—Gastrointestinal haemorrhage—Fluorouracil—urinary bladder cancer	0.000293	0.00429	CcSEcCtD
Vorinostat—Pancytopenia—Thiotepa—urinary bladder cancer	0.000291	0.00426	CcSEcCtD
Vorinostat—Embolism—Doxorubicin—urinary bladder cancer	0.000283	0.00415	CcSEcCtD
Vorinostat—Blood creatinine increased—Gemcitabine—urinary bladder cancer	0.000279	0.00409	CcSEcCtD
Vorinostat—Gastrointestinal haemorrhage—Cisplatin—urinary bladder cancer	0.000278	0.00407	CcSEcCtD
Vorinostat—Hyperglycaemia—Thiotepa—urinary bladder cancer	0.000276	0.00405	CcSEcCtD
Vorinostat—Body temperature increased—Mitomycin—urinary bladder cancer	0.000274	0.00401	CcSEcCtD
Vorinostat—Hypokalaemia—Gemcitabine—urinary bladder cancer	0.000271	0.00397	CcSEcCtD
Vorinostat—Abscess—Methotrexate—urinary bladder cancer	0.000265	0.00389	CcSEcCtD
Vorinostat—Blood creatinine increased—Cisplatin—urinary bladder cancer	0.00026	0.00381	CcSEcCtD
Vorinostat—Dehydration—Cisplatin—urinary bladder cancer	0.000258	0.00379	CcSEcCtD
Vorinostat—Hypokalaemia—Cisplatin—urinary bladder cancer	0.000253	0.0037	CcSEcCtD
Vorinostat—Asthenia—Mitomycin—urinary bladder cancer	0.000248	0.00364	CcSEcCtD
Vorinostat—Abscess—Epirubicin—urinary bladder cancer	0.000248	0.00364	CcSEcCtD
Vorinostat—Pancytopenia—Gemcitabine—urinary bladder cancer	0.000245	0.00358	CcSEcCtD
Vorinostat—Neutropenia—Gemcitabine—urinary bladder cancer	0.000241	0.00353	CcSEcCtD
Vorinostat—Pancytopenia—Fluorouracil—urinary bladder cancer	0.000241	0.00352	CcSEcCtD
Vorinostat—Proteinuria—Methotrexate—urinary bladder cancer	0.000239	0.0035	CcSEcCtD
Vorinostat—Diarrhoea—Mitomycin—urinary bladder cancer	0.000237	0.00347	CcSEcCtD
Vorinostat—Protein urine present—Methotrexate—urinary bladder cancer	0.000236	0.00345	CcSEcCtD
Vorinostat—Upper respiratory tract infection—Fluorouracil—urinary bladder cancer	0.000235	0.00345	CcSEcCtD
Vorinostat—Hyperglycaemia—Gemcitabine—urinary bladder cancer	0.000232	0.0034	CcSEcCtD
Vorinostat—Neoplasm malignant—Epirubicin—urinary bladder cancer	0.00023	0.00337	CcSEcCtD
Vorinostat—Abscess—Doxorubicin—urinary bladder cancer	0.00023	0.00337	CcSEcCtD
Vorinostat—Dizziness—Mitomycin—urinary bladder cancer	0.000229	0.00336	CcSEcCtD
Vorinostat—Pancytopenia—Cisplatin—urinary bladder cancer	0.000228	0.00334	CcSEcCtD
Vorinostat—Acute coronary syndrome—Gemcitabine—urinary bladder cancer	0.000226	0.00332	CcSEcCtD
Vorinostat—Myocardial infarction—Gemcitabine—urinary bladder cancer	0.000225	0.0033	CcSEcCtD
Vorinostat—Acute coronary syndrome—Fluorouracil—urinary bladder cancer	0.000223	0.00326	CcSEcCtD
Vorinostat—Myocardial infarction—Fluorouracil—urinary bladder cancer	0.000221	0.00324	CcSEcCtD
Vorinostat—Vomiting—Mitomycin—urinary bladder cancer	0.00022	0.00323	CcSEcCtD
Vorinostat—Chills—Thiotepa—urinary bladder cancer	0.00022	0.00322	CcSEcCtD
Vorinostat—Headache—Mitomycin—urinary bladder cancer	0.000217	0.00318	CcSEcCtD
Vorinostat—Alopecia—Thiotepa—urinary bladder cancer	0.000217	0.00317	CcSEcCtD
Vorinostat—Neoplasm malignant—Doxorubicin—urinary bladder cancer	0.000213	0.00312	CcSEcCtD
Vorinostat—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.000211	0.00309	CcSEcCtD
Vorinostat—Pulmonary embolism—Methotrexate—urinary bladder cancer	0.00021	0.00308	CcSEcCtD
Vorinostat—Myocardial infarction—Cisplatin—urinary bladder cancer	0.00021	0.00307	CcSEcCtD
Vorinostat—Pancytopenia—Etoposide—urinary bladder cancer	0.000209	0.00306	CcSEcCtD
Vorinostat—Neutropenia—Etoposide—urinary bladder cancer	0.000206	0.00301	CcSEcCtD
Vorinostat—Nausea—Mitomycin—urinary bladder cancer	0.000206	0.00301	CcSEcCtD
Vorinostat—Oedema peripheral—Gemcitabine—urinary bladder cancer	0.000203	0.00298	CcSEcCtD
Vorinostat—Anaemia—Thiotepa—urinary bladder cancer	0.000197	0.00289	CcSEcCtD
Vorinostat—Pulmonary embolism—Epirubicin—urinary bladder cancer	0.000197	0.00288	CcSEcCtD
Vorinostat—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000193	0.00283	CcSEcCtD
Vorinostat—Myocardial infarction—Etoposide—urinary bladder cancer	0.000192	0.00282	CcSEcCtD
Vorinostat—Leukopenia—Thiotepa—urinary bladder cancer	0.000191	0.0028	CcSEcCtD
Vorinostat—Cough—Thiotepa—urinary bladder cancer	0.000186	0.00273	CcSEcCtD
Vorinostat—Chills—Gemcitabine—urinary bladder cancer	0.000185	0.00271	CcSEcCtD
Vorinostat—Sepsis—Methotrexate—urinary bladder cancer	0.000182	0.00267	CcSEcCtD
Vorinostat—Alopecia—Gemcitabine—urinary bladder cancer	0.000182	0.00267	CcSEcCtD
Vorinostat—Pulmonary embolism—Doxorubicin—urinary bladder cancer	0.000182	0.00266	CcSEcCtD
Vorinostat—Alopecia—Fluorouracil—urinary bladder cancer	0.000179	0.00262	CcSEcCtD
Vorinostat—Infection—Thiotepa—urinary bladder cancer	0.000173	0.00253	CcSEcCtD
Vorinostat—Sepsis—Epirubicin—urinary bladder cancer	0.000171	0.0025	CcSEcCtD
Vorinostat—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000171	0.0025	CcSEcCtD
Vorinostat—Alopecia—Cisplatin—urinary bladder cancer	0.00017	0.00249	CcSEcCtD
Vorinostat—Anorexia—Thiotepa—urinary bladder cancer	0.000166	0.00243	CcSEcCtD
Vorinostat—Anaemia—Gemcitabine—urinary bladder cancer	0.000166	0.00243	CcSEcCtD
Vorinostat—Anaemia—Fluorouracil—urinary bladder cancer	0.000163	0.00239	CcSEcCtD
Vorinostat—Dermatitis exfoliative—Methotrexate—urinary bladder cancer	0.000162	0.00237	CcSEcCtD
Vorinostat—Muscle spasms—Cisplatin—urinary bladder cancer	0.000161	0.00236	CcSEcCtD
Vorinostat—Leukopenia—Gemcitabine—urinary bladder cancer	0.000161	0.00235	CcSEcCtD
Vorinostat—Chills—Etoposide—urinary bladder cancer	0.000158	0.00231	CcSEcCtD
Vorinostat—Leukopenia—Fluorouracil—urinary bladder cancer	0.000158	0.00231	CcSEcCtD
Vorinostat—Sepsis—Doxorubicin—urinary bladder cancer	0.000158	0.00231	CcSEcCtD
Vorinostat—Cough—Gemcitabine—urinary bladder cancer	0.000157	0.00229	CcSEcCtD
Vorinostat—Alopecia—Etoposide—urinary bladder cancer	0.000156	0.00228	CcSEcCtD
Vorinostat—Lethargy—Methotrexate—urinary bladder cancer	0.000156	0.00228	CcSEcCtD
Vorinostat—Anaemia—Cisplatin—urinary bladder cancer	0.000155	0.00227	CcSEcCtD
Vorinostat—Chest pain—Gemcitabine—urinary bladder cancer	0.000153	0.00224	CcSEcCtD
Vorinostat—Decreased appetite—Thiotepa—urinary bladder cancer	0.000151	0.00222	CcSEcCtD
Vorinostat—Dermatitis exfoliative—Epirubicin—urinary bladder cancer	0.000151	0.00222	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00015	0.0022	CcSEcCtD
Vorinostat—Chest pain—Fluorouracil—urinary bladder cancer	0.00015	0.0022	CcSEcCtD
Vorinostat—Fatigue—Thiotepa—urinary bladder cancer	0.00015	0.0022	CcSEcCtD
Vorinostat—Dysgeusia—Etoposide—urinary bladder cancer	0.00015	0.0022	CcSEcCtD
Vorinostat—Leukopenia—Cisplatin—urinary bladder cancer	0.00015	0.00219	CcSEcCtD
Vorinostat—Constipation—Thiotepa—urinary bladder cancer	0.000149	0.00218	CcSEcCtD
Vorinostat—Muscle spasms—Etoposide—urinary bladder cancer	0.000147	0.00216	CcSEcCtD
Vorinostat—Lethargy—Epirubicin—urinary bladder cancer	0.000146	0.00213	CcSEcCtD
Vorinostat—Infection—Gemcitabine—urinary bladder cancer	0.000146	0.00213	CcSEcCtD
Vorinostat—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000143	0.0021	CcSEcCtD
Vorinostat—Infection—Fluorouracil—urinary bladder cancer	0.000143	0.0021	CcSEcCtD
Vorinostat—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.000143	0.00209	CcSEcCtD
Vorinostat—Anaemia—Etoposide—urinary bladder cancer	0.000142	0.00208	CcSEcCtD
Vorinostat—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000141	0.00207	CcSEcCtD
Vorinostat—Dermatitis exfoliative—Doxorubicin—urinary bladder cancer	0.00014	0.00205	CcSEcCtD
Vorinostat—Anorexia—Gemcitabine—urinary bladder cancer	0.00014	0.00205	CcSEcCtD
Vorinostat—Body temperature increased—Thiotepa—urinary bladder cancer	0.000138	0.00202	CcSEcCtD
Vorinostat—Anorexia—Fluorouracil—urinary bladder cancer	0.000137	0.00201	CcSEcCtD
Vorinostat—Leukopenia—Etoposide—urinary bladder cancer	0.000137	0.00201	CcSEcCtD
Vorinostat—Infection—Cisplatin—urinary bladder cancer	0.000136	0.00199	CcSEcCtD
Vorinostat—Loss of consciousness—Etoposide—urinary bladder cancer	0.000135	0.00197	CcSEcCtD
Vorinostat—Lethargy—Doxorubicin—urinary bladder cancer	0.000135	0.00197	CcSEcCtD
Vorinostat—Cough—Etoposide—urinary bladder cancer	0.000134	0.00196	CcSEcCtD
Vorinostat—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000134	0.00196	CcSEcCtD
Vorinostat—Blood creatinine increased—Epirubicin—urinary bladder cancer	0.000134	0.00196	CcSEcCtD
Vorinostat—Dehydration—Epirubicin—urinary bladder cancer	0.000133	0.00194	CcSEcCtD
Vorinostat—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.000132	0.00193	CcSEcCtD
Vorinostat—Chest pain—Etoposide—urinary bladder cancer	0.00013	0.00191	CcSEcCtD
Vorinostat—Anorexia—Cisplatin—urinary bladder cancer	0.00013	0.00191	CcSEcCtD
Vorinostat—Hypokalaemia—Epirubicin—urinary bladder cancer	0.00013	0.0019	CcSEcCtD
Vorinostat—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000127	0.00187	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000126	0.00185	CcSEcCtD
Vorinostat—Fatigue—Gemcitabine—urinary bladder cancer	0.000126	0.00185	CcSEcCtD
Vorinostat—Constipation—Gemcitabine—urinary bladder cancer	0.000125	0.00184	CcSEcCtD
Vorinostat—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000125	0.00183	CcSEcCtD
Vorinostat—Pancytopenia—Methotrexate—urinary bladder cancer	0.000125	0.00183	CcSEcCtD
Vorinostat—Asthenia—Thiotepa—urinary bladder cancer	0.000125	0.00183	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000124	0.00182	CcSEcCtD
Vorinostat—Infection—Etoposide—urinary bladder cancer	0.000124	0.00182	CcSEcCtD
Vorinostat—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000124	0.00181	CcSEcCtD
Vorinostat—Neutropenia—Methotrexate—urinary bladder cancer	0.000123	0.00181	CcSEcCtD
Vorinostat—Pruritus—Thiotepa—urinary bladder cancer	0.000123	0.00181	CcSEcCtD
Vorinostat—Dehydration—Doxorubicin—urinary bladder cancer	0.000123	0.0018	CcSEcCtD
Vorinostat—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000122	0.00179	CcSEcCtD
Vorinostat—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000122	0.00179	CcSEcCtD
Vorinostat—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.00012	0.00176	CcSEcCtD
Vorinostat—Anorexia—Etoposide—urinary bladder cancer	0.000119	0.00175	CcSEcCtD
Vorinostat—Diarrhoea—Thiotepa—urinary bladder cancer	0.000119	0.00175	CcSEcCtD
Vorinostat—Decreased appetite—Cisplatin—urinary bladder cancer	0.000119	0.00174	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000118	0.00173	CcSEcCtD
Vorinostat—Pancytopenia—Epirubicin—urinary bladder cancer	0.000117	0.00172	CcSEcCtD
Vorinostat—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000116	0.0017	CcSEcCtD
Vorinostat—Neutropenia—Epirubicin—urinary bladder cancer	0.000115	0.00169	CcSEcCtD
Vorinostat—Dizziness—Thiotepa—urinary bladder cancer	0.000115	0.00169	CcSEcCtD
Vorinostat—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000115	0.00168	CcSEcCtD
Vorinostat—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000114	0.00167	CcSEcCtD
Vorinostat—Weight decreased—Epirubicin—urinary bladder cancer	0.000112	0.00163	CcSEcCtD
Vorinostat—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000111	0.00163	CcSEcCtD
Vorinostat—Vomiting—Thiotepa—urinary bladder cancer	0.000111	0.00162	CcSEcCtD
Vorinostat—Headache—Thiotepa—urinary bladder cancer	0.000109	0.0016	CcSEcCtD
Vorinostat—Decreased appetite—Etoposide—urinary bladder cancer	0.000109	0.00159	CcSEcCtD
Vorinostat—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000108	0.00159	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000108	0.00158	CcSEcCtD
Vorinostat—Body temperature increased—Cisplatin—urinary bladder cancer	0.000108	0.00158	CcSEcCtD
Vorinostat—Fatigue—Etoposide—urinary bladder cancer	0.000108	0.00158	CcSEcCtD
Vorinostat—Constipation—Etoposide—urinary bladder cancer	0.000107	0.00157	CcSEcCtD
Vorinostat—Neutropenia—Doxorubicin—urinary bladder cancer	0.000107	0.00156	CcSEcCtD
Vorinostat—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000106	0.00155	CcSEcCtD
Vorinostat—Asthenia—Gemcitabine—urinary bladder cancer	0.000105	0.00154	CcSEcCtD
Vorinostat—Pruritus—Gemcitabine—urinary bladder cancer	0.000104	0.00152	CcSEcCtD
Vorinostat—Nausea—Thiotepa—urinary bladder cancer	0.000103	0.00152	CcSEcCtD
Vorinostat—Weight decreased—Doxorubicin—urinary bladder cancer	0.000103	0.00151	CcSEcCtD
Vorinostat—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000103	0.00151	CcSEcCtD
Vorinostat—Pruritus—Fluorouracil—urinary bladder cancer	0.000102	0.00149	CcSEcCtD
Vorinostat—Diarrhoea—Gemcitabine—urinary bladder cancer	0.0001	0.00147	CcSEcCtD
Vorinostat—Body temperature increased—Etoposide—urinary bladder cancer	9.89e-05	0.00145	CcSEcCtD
Vorinostat—Diarrhoea—Fluorouracil—urinary bladder cancer	9.85e-05	0.00144	CcSEcCtD
Vorinostat—Asthenia—Cisplatin—urinary bladder cancer	9.8e-05	0.00144	CcSEcCtD
Vorinostat—Oedema peripheral—Epirubicin—urinary bladder cancer	9.72e-05	0.00142	CcSEcCtD
Vorinostat—Dizziness—Fluorouracil—urinary bladder cancer	9.52e-05	0.0014	CcSEcCtD
Vorinostat—Chills—Methotrexate—urinary bladder cancer	9.46e-05	0.00139	CcSEcCtD
Vorinostat—Diarrhoea—Cisplatin—urinary bladder cancer	9.34e-05	0.00137	CcSEcCtD
Vorinostat—Alopecia—Methotrexate—urinary bladder cancer	9.32e-05	0.00137	CcSEcCtD
Vorinostat—Vomiting—Gemcitabine—urinary bladder cancer	9.31e-05	0.00136	CcSEcCtD
Vorinostat—Headache—Gemcitabine—urinary bladder cancer	9.18e-05	0.00134	CcSEcCtD
Vorinostat—Vomiting—Fluorouracil—urinary bladder cancer	9.16e-05	0.00134	CcSEcCtD
Vorinostat—Headache—Fluorouracil—urinary bladder cancer	9.02e-05	0.00132	CcSEcCtD
Vorinostat—Oedema peripheral—Doxorubicin—urinary bladder cancer	9e-05	0.00132	CcSEcCtD
Vorinostat—Dysgeusia—Methotrexate—urinary bladder cancer	8.99e-05	0.00132	CcSEcCtD
Vorinostat—Asthenia—Etoposide—urinary bladder cancer	8.97e-05	0.00132	CcSEcCtD
Vorinostat—Chills—Epirubicin—urinary bladder cancer	8.86e-05	0.0013	CcSEcCtD
Vorinostat—Pruritus—Etoposide—urinary bladder cancer	8.85e-05	0.0013	CcSEcCtD
Vorinostat—Alopecia—Epirubicin—urinary bladder cancer	8.72e-05	0.00128	CcSEcCtD
Vorinostat—Nausea—Gemcitabine—urinary bladder cancer	8.7e-05	0.00127	CcSEcCtD
Vorinostat—Vomiting—Cisplatin—urinary bladder cancer	8.68e-05	0.00127	CcSEcCtD
Vorinostat—Diarrhoea—Etoposide—urinary bladder cancer	8.56e-05	0.00125	CcSEcCtD
Vorinostat—Nausea—Fluorouracil—urinary bladder cancer	8.56e-05	0.00125	CcSEcCtD
Vorinostat—Anaemia—Methotrexate—urinary bladder cancer	8.49e-05	0.00124	CcSEcCtD
Vorinostat—Dysgeusia—Epirubicin—urinary bladder cancer	8.41e-05	0.00123	CcSEcCtD
Vorinostat—Dizziness—Etoposide—urinary bladder cancer	8.27e-05	0.00121	CcSEcCtD
Vorinostat—Muscle spasms—Epirubicin—urinary bladder cancer	8.26e-05	0.00121	CcSEcCtD
Vorinostat—Leukopenia—Methotrexate—urinary bladder cancer	8.22e-05	0.0012	CcSEcCtD
Vorinostat—Chills—Doxorubicin—urinary bladder cancer	8.19e-05	0.0012	CcSEcCtD
Vorinostat—Nausea—Cisplatin—urinary bladder cancer	8.11e-05	0.00119	CcSEcCtD
Vorinostat—Alopecia—Doxorubicin—urinary bladder cancer	8.07e-05	0.00118	CcSEcCtD
Vorinostat—Cough—Methotrexate—urinary bladder cancer	8.01e-05	0.00117	CcSEcCtD
Vorinostat—Vomiting—Etoposide—urinary bladder cancer	7.95e-05	0.00117	CcSEcCtD
Vorinostat—Anaemia—Epirubicin—urinary bladder cancer	7.94e-05	0.00116	CcSEcCtD
Vorinostat—Headache—Etoposide—urinary bladder cancer	7.84e-05	0.00115	CcSEcCtD
Vorinostat—Chest pain—Methotrexate—urinary bladder cancer	7.82e-05	0.00115	CcSEcCtD
Vorinostat—Dysgeusia—Doxorubicin—urinary bladder cancer	7.78e-05	0.00114	CcSEcCtD
Vorinostat—Syncope—Epirubicin—urinary bladder cancer	7.7e-05	0.00113	CcSEcCtD
Vorinostat—Leukopenia—Epirubicin—urinary bladder cancer	7.69e-05	0.00113	CcSEcCtD
Vorinostat—Muscle spasms—Doxorubicin—urinary bladder cancer	7.64e-05	0.00112	CcSEcCtD
Vorinostat—Loss of consciousness—Epirubicin—urinary bladder cancer	7.55e-05	0.00111	CcSEcCtD
Vorinostat—Cough—Epirubicin—urinary bladder cancer	7.5e-05	0.0011	CcSEcCtD
Vorinostat—Infection—Methotrexate—urinary bladder cancer	7.44e-05	0.00109	CcSEcCtD
Vorinostat—Nausea—Etoposide—urinary bladder cancer	7.43e-05	0.00109	CcSEcCtD
Vorinostat—Anaemia—Doxorubicin—urinary bladder cancer	7.35e-05	0.00108	CcSEcCtD
Vorinostat—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.34e-05	0.00107	CcSEcCtD
Vorinostat—Chest pain—Epirubicin—urinary bladder cancer	7.31e-05	0.00107	CcSEcCtD
Vorinostat—Dry mouth—Epirubicin—urinary bladder cancer	7.15e-05	0.00105	CcSEcCtD
Vorinostat—Anorexia—Methotrexate—urinary bladder cancer	7.14e-05	0.00105	CcSEcCtD
Vorinostat—Syncope—Doxorubicin—urinary bladder cancer	7.13e-05	0.00104	CcSEcCtD
Vorinostat—Leukopenia—Doxorubicin—urinary bladder cancer	7.12e-05	0.00104	CcSEcCtD
Vorinostat—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.99e-05	0.00102	CcSEcCtD
Vorinostat—Infection—Epirubicin—urinary bladder cancer	6.97e-05	0.00102	CcSEcCtD
Vorinostat—Cough—Doxorubicin—urinary bladder cancer	6.94e-05	0.00102	CcSEcCtD
Vorinostat—Shock—Epirubicin—urinary bladder cancer	6.9e-05	0.00101	CcSEcCtD
Vorinostat—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.87e-05	0.00101	CcSEcCtD
Vorinostat—Chest pain—Doxorubicin—urinary bladder cancer	6.77e-05	0.000992	CcSEcCtD
Vorinostat—Anorexia—Epirubicin—urinary bladder cancer	6.68e-05	0.000979	CcSEcCtD
Vorinostat—Dry mouth—Doxorubicin—urinary bladder cancer	6.62e-05	0.00097	CcSEcCtD
Vorinostat—Decreased appetite—Methotrexate—urinary bladder cancer	6.51e-05	0.000954	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.47e-05	0.000948	CcSEcCtD
Vorinostat—Fatigue—Methotrexate—urinary bladder cancer	6.46e-05	0.000947	CcSEcCtD
Vorinostat—Infection—Doxorubicin—urinary bladder cancer	6.45e-05	0.000944	CcSEcCtD
Vorinostat—Shock—Doxorubicin—urinary bladder cancer	6.38e-05	0.000935	CcSEcCtD
Vorinostat—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.35e-05	0.000931	CcSEcCtD
Vorinostat—Anorexia—Doxorubicin—urinary bladder cancer	6.18e-05	0.000906	CcSEcCtD
Vorinostat—Decreased appetite—Epirubicin—urinary bladder cancer	6.1e-05	0.000893	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.05e-05	0.000887	CcSEcCtD
Vorinostat—Fatigue—Epirubicin—urinary bladder cancer	6.05e-05	0.000886	CcSEcCtD
Vorinostat—Constipation—Epirubicin—urinary bladder cancer	6e-05	0.000879	CcSEcCtD
Vorinostat—Body temperature increased—Methotrexate—urinary bladder cancer	5.92e-05	0.000868	CcSEcCtD
Vorinostat—Decreased appetite—Doxorubicin—urinary bladder cancer	5.64e-05	0.000826	CcSEcCtD
Vorinostat—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.6e-05	0.000821	CcSEcCtD
Vorinostat—Fatigue—Doxorubicin—urinary bladder cancer	5.59e-05	0.00082	CcSEcCtD
Vorinostat—Constipation—Doxorubicin—urinary bladder cancer	5.55e-05	0.000813	CcSEcCtD
Vorinostat—Body temperature increased—Epirubicin—urinary bladder cancer	5.54e-05	0.000812	CcSEcCtD
Vorinostat—Asthenia—Methotrexate—urinary bladder cancer	5.38e-05	0.000788	CcSEcCtD
Vorinostat—Pruritus—Methotrexate—urinary bladder cancer	5.3e-05	0.000777	CcSEcCtD
Vorinostat—Body temperature increased—Doxorubicin—urinary bladder cancer	5.13e-05	0.000751	CcSEcCtD
Vorinostat—Diarrhoea—Methotrexate—urinary bladder cancer	5.13e-05	0.000751	CcSEcCtD
Vorinostat—Asthenia—Epirubicin—urinary bladder cancer	5.03e-05	0.000737	CcSEcCtD
Vorinostat—Pruritus—Epirubicin—urinary bladder cancer	4.96e-05	0.000727	CcSEcCtD
Vorinostat—Dizziness—Methotrexate—urinary bladder cancer	4.95e-05	0.000726	CcSEcCtD
Vorinostat—Diarrhoea—Epirubicin—urinary bladder cancer	4.8e-05	0.000703	CcSEcCtD
Vorinostat—Vomiting—Methotrexate—urinary bladder cancer	4.76e-05	0.000698	CcSEcCtD
Vorinostat—Headache—Methotrexate—urinary bladder cancer	4.69e-05	0.000688	CcSEcCtD
Vorinostat—Asthenia—Doxorubicin—urinary bladder cancer	4.65e-05	0.000682	CcSEcCtD
Vorinostat—Dizziness—Epirubicin—urinary bladder cancer	4.64e-05	0.000679	CcSEcCtD
Vorinostat—Pruritus—Doxorubicin—urinary bladder cancer	4.59e-05	0.000673	CcSEcCtD
Vorinostat—Vomiting—Epirubicin—urinary bladder cancer	4.46e-05	0.000653	CcSEcCtD
Vorinostat—Nausea—Methotrexate—urinary bladder cancer	4.45e-05	0.000652	CcSEcCtD
Vorinostat—Diarrhoea—Doxorubicin—urinary bladder cancer	4.44e-05	0.00065	CcSEcCtD
Vorinostat—Headache—Epirubicin—urinary bladder cancer	4.39e-05	0.000644	CcSEcCtD
Vorinostat—Dizziness—Doxorubicin—urinary bladder cancer	4.29e-05	0.000629	CcSEcCtD
Vorinostat—Nausea—Epirubicin—urinary bladder cancer	4.16e-05	0.00061	CcSEcCtD
Vorinostat—Vomiting—Doxorubicin—urinary bladder cancer	4.13e-05	0.000604	CcSEcCtD
Vorinostat—Headache—Doxorubicin—urinary bladder cancer	4.06e-05	0.000596	CcSEcCtD
Vorinostat—Nausea—Doxorubicin—urinary bladder cancer	3.85e-05	0.000565	CcSEcCtD
Vorinostat—NCOR1—Signaling Pathways—TERT—urinary bladder cancer	8.22e-06	5.58e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—IGF1—urinary bladder cancer	8.21e-06	5.57e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—FGFR3—urinary bladder cancer	8.21e-06	5.57e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—PTGS2—urinary bladder cancer	8.17e-06	5.55e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—RHOA—urinary bladder cancer	8.15e-06	5.53e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—EP300—urinary bladder cancer	8.1e-06	5.5e-05	CbGpPWpGaD
Vorinostat—HDAC8—Disease—EP300—urinary bladder cancer	8.09e-06	5.49e-05	CbGpPWpGaD
Vorinostat—HDAC1—Gene Expression—CREBBP—urinary bladder cancer	8.05e-06	5.46e-05	CbGpPWpGaD
Vorinostat—NCOR1—Metabolism—PPARG—urinary bladder cancer	7.99e-06	5.43e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—ESR1—urinary bladder cancer	7.97e-06	5.41e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—CDKN1A—urinary bladder cancer	7.95e-06	5.4e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—PTEN—urinary bladder cancer	7.93e-06	5.39e-05	CbGpPWpGaD
Vorinostat—HDAC11—Disease—HRAS—urinary bladder cancer	7.92e-06	5.37e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—CXCL8—urinary bladder cancer	7.91e-06	5.37e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—SRC—urinary bladder cancer	7.88e-06	5.35e-05	CbGpPWpGaD
Vorinostat—HDAC8—Disease—SRC—urinary bladder cancer	7.87e-06	5.34e-05	CbGpPWpGaD
Vorinostat—HDAC6—Disease—KRAS—urinary bladder cancer	7.8e-06	5.3e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—CREBBP—urinary bladder cancer	7.78e-06	5.28e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—IGF1—urinary bladder cancer	7.68e-06	5.21e-05	CbGpPWpGaD
Vorinostat—NCOR1—Metabolism—CREBBP—urinary bladder cancer	7.68e-06	5.21e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—ERBB2—urinary bladder cancer	7.68e-06	5.21e-05	CbGpPWpGaD
Vorinostat—HDAC4—Disease—MYC—urinary bladder cancer	7.64e-06	5.18e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—NCOR1—urinary bladder cancer	7.6e-06	5.16e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—EP300—urinary bladder cancer	7.57e-06	5.14e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—IL2—urinary bladder cancer	7.56e-06	5.13e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—IL2—urinary bladder cancer	7.55e-06	5.13e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—ERBB2—urinary bladder cancer	7.55e-06	5.12e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—FGFR3—urinary bladder cancer	7.54e-06	5.12e-05	CbGpPWpGaD
Vorinostat—HDAC2—Gene Expression—NCOR1—urinary bladder cancer	7.54e-06	5.12e-05	CbGpPWpGaD
Vorinostat—HDAC1—Hemostasis—TP53—urinary bladder cancer	7.53e-06	5.11e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—RHOA—urinary bladder cancer	7.52e-06	5.11e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—RBX1—urinary bladder cancer	7.52e-06	5.1e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—PTGS2—urinary bladder cancer	7.51e-06	5.1e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—CREBBP—urinary bladder cancer	7.48e-06	5.07e-05	CbGpPWpGaD
Vorinostat—HDAC4—Disease—EGFR—urinary bladder cancer	7.47e-06	5.07e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—CCND1—urinary bladder cancer	7.37e-06	5e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—SRC—urinary bladder cancer	7.36e-06	4.99e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—ESR1—urinary bladder cancer	7.33e-06	4.97e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling by NGF—HRAS—urinary bladder cancer	7.32e-06	4.97e-05	CbGpPWpGaD
Vorinostat—HDAC1—Hemostasis—HRAS—urinary bladder cancer	7.2e-06	4.89e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—MMP9—urinary bladder cancer	7.16e-06	4.86e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—CXCL8—urinary bladder cancer	7.16e-06	4.86e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—CDKN1A—urinary bladder cancer	7.14e-06	4.85e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—CDKN1A—urinary bladder cancer	7.13e-06	4.84e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—PTEN—urinary bladder cancer	7.13e-06	4.84e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—PTEN—urinary bladder cancer	7.12e-06	4.83e-05	CbGpPWpGaD
Vorinostat—HDAC1—Cell Cycle—TP53—urinary bladder cancer	7.1e-06	4.82e-05	CbGpPWpGaD
Vorinostat—HDAC2—Gene Expression—ERCC2—urinary bladder cancer	7.09e-06	4.81e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—TSC1—urinary bladder cancer	7.07e-06	4.8e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—MYC—urinary bladder cancer	7.06e-06	4.79e-05	CbGpPWpGaD
Vorinostat—HDAC4—Disease—KRAS—urinary bladder cancer	7.06e-06	4.79e-05	CbGpPWpGaD
Vorinostat—HDAC8—Disease—MYC—urinary bladder cancer	7.05e-06	4.78e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—RHOA—urinary bladder cancer	7.04e-06	4.78e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—NCOR1—urinary bladder cancer	7e-06	4.75e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—CREBBP—urinary bladder cancer	6.99e-06	4.74e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—ERBB2—urinary bladder cancer	6.97e-06	4.73e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—EGFR—urinary bladder cancer	6.9e-06	4.69e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—IGF1—urinary bladder cancer	6.9e-06	4.68e-05	CbGpPWpGaD
Vorinostat—HDAC8—Disease—EGFR—urinary bladder cancer	6.89e-06	4.68e-05	CbGpPWpGaD
Vorinostat—NR0B1—Gene Expression—MYC—urinary bladder cancer	6.89e-06	4.68e-05	CbGpPWpGaD
Vorinostat—HDAC3—Metabolism—PTGS2—urinary bladder cancer	6.84e-06	4.65e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—IL2—urinary bladder cancer	6.84e-06	4.64e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—EP300—urinary bladder cancer	6.8e-06	4.61e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—EP300—urinary bladder cancer	6.79e-06	4.61e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—EP300—urinary bladder cancer	6.78e-06	4.6e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—RHOA—urinary bladder cancer	6.76e-06	4.59e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—JAG1—urinary bladder cancer	6.73e-06	4.57e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—TERT—urinary bladder cancer	6.7e-06	4.55e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—CCND1—urinary bladder cancer	6.67e-06	4.53e-05	CbGpPWpGaD
Vorinostat—HDAC6—Disease—HRAS—urinary bladder cancer	6.63e-06	4.5e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—SRC—urinary bladder cancer	6.61e-06	4.49e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—CXCL8—urinary bladder cancer	6.61e-06	4.48e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—SRC—urinary bladder cancer	6.6e-06	4.48e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—MYC—urinary bladder cancer	6.59e-06	4.48e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—SRC—urinary bladder cancer	6.59e-06	4.47e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—ERCC2—urinary bladder cancer	6.58e-06	4.47e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—CDKN1A—urinary bladder cancer	6.56e-06	4.46e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—PTEN—urinary bladder cancer	6.55e-06	4.45e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—KRAS—urinary bladder cancer	6.52e-06	4.43e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—ERBB2—urinary bladder cancer	6.52e-06	4.42e-05	CbGpPWpGaD
Vorinostat—HDAC8—Disease—KRAS—urinary bladder cancer	6.51e-06	4.42e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—MMP9—urinary bladder cancer	6.47e-06	4.39e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—CDKN1A—urinary bladder cancer	6.45e-06	4.38e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—EGFR—urinary bladder cancer	6.45e-06	4.38e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—PTEN—urinary bladder cancer	6.44e-06	4.37e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—CREBBP—urinary bladder cancer	6.42e-06	4.36e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—IGF1—urinary bladder cancer	6.34e-06	4.3e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—RHOA—urinary bladder cancer	6.32e-06	4.29e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—IL2—urinary bladder cancer	6.31e-06	4.28e-05	CbGpPWpGaD
Vorinostat—NCOR1—Metabolism—PTGS2—urinary bladder cancer	6.29e-06	4.27e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—ERBB2—urinary bladder cancer	6.26e-06	4.25e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—EP300—urinary bladder cancer	6.25e-06	4.24e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—MTHFR—urinary bladder cancer	6.18e-06	4.2e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—CXCL8—urinary bladder cancer	6.18e-06	4.19e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—TERT—urinary bladder cancer	6.17e-06	4.19e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—CCND1—urinary bladder cancer	6.15e-06	4.18e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—FGFR3—urinary bladder cancer	6.15e-06	4.17e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—EP300—urinary bladder cancer	6.14e-06	4.17e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—PTGS2—urinary bladder cancer	6.12e-06	4.16e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—KRAS—urinary bladder cancer	6.09e-06	4.14e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—SRC—urinary bladder cancer	6.07e-06	4.12e-05	CbGpPWpGaD
Vorinostat—HDAC4—Disease—HRAS—urinary bladder cancer	6e-06	4.07e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—MMP9—urinary bladder cancer	5.97e-06	4.06e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—ESR1—urinary bladder cancer	5.97e-06	4.05e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—SRC—urinary bladder cancer	5.97e-06	4.05e-05	CbGpPWpGaD
Vorinostat—HDAC3—Metabolism—PTEN—urinary bladder cancer	5.97e-06	4.05e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—CDKN1A—urinary bladder cancer	5.95e-06	4.04e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—PTEN—urinary bladder cancer	5.94e-06	4.03e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—MYC—urinary bladder cancer	5.92e-06	4.02e-05	CbGpPWpGaD
Vorinostat—HDAC2—Gene Expression—ESR1—urinary bladder cancer	5.92e-06	4.02e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—MYC—urinary bladder cancer	5.91e-06	4.01e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—IL2—urinary bladder cancer	5.9e-06	4.01e-05	CbGpPWpGaD
Vorinostat—NCOR1—Gene Expression—MYC—urinary bladder cancer	5.86e-06	3.98e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—ERBB2—urinary bladder cancer	5.85e-06	3.97e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—RHOA—urinary bladder cancer	5.81e-06	3.94e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—TP53—urinary bladder cancer	5.8e-06	3.93e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—EGFR—urinary bladder cancer	5.79e-06	3.93e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—EGFR—urinary bladder cancer	5.78e-06	3.93e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—CCND1—urinary bladder cancer	5.76e-06	3.91e-05	CbGpPWpGaD
Vorinostat—HDAC3—Metabolism—EP300—urinary bladder cancer	5.69e-06	3.86e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—EP300—urinary bladder cancer	5.66e-06	3.84e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—FGFR3—urinary bladder cancer	5.66e-06	3.84e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—MMP9—urinary bladder cancer	5.59e-06	3.79e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—CDKN1A—urinary bladder cancer	5.57e-06	3.78e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—PTEN—urinary bladder cancer	5.56e-06	3.77e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—CXCL8—urinary bladder cancer	5.55e-06	3.77e-05	CbGpPWpGaD
Vorinostat—HDAC11—Signaling Pathways—HRAS—urinary bladder cancer	5.54e-06	3.76e-05	CbGpPWpGaD
Vorinostat—HDAC8—Disease—HRAS—urinary bladder cancer	5.54e-06	3.76e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—SRC—urinary bladder cancer	5.51e-06	3.74e-05	CbGpPWpGaD
Vorinostat—NCOR1—Metabolism—PTEN—urinary bladder cancer	5.48e-06	3.72e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—KRAS—urinary bladder cancer	5.47e-06	3.71e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—KRAS—urinary bladder cancer	5.46e-06	3.71e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—KRAS—urinary bladder cancer	5.46e-06	3.7e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—S100B—urinary bladder cancer	5.45e-06	3.7e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—MYC—urinary bladder cancer	5.44e-06	3.69e-05	CbGpPWpGaD
Vorinostat—HDAC2—Gene Expression—PPARG—urinary bladder cancer	5.4e-06	3.67e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—ERBB2—urinary bladder cancer	5.38e-06	3.65e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—CDKN1A—urinary bladder cancer	5.35e-06	3.63e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—MYC—urinary bladder cancer	5.35e-06	3.63e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—PTEN—urinary bladder cancer	5.34e-06	3.62e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—EGFR—urinary bladder cancer	5.32e-06	3.61e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—IL2—urinary bladder cancer	5.3e-06	3.6e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—EP300—urinary bladder cancer	5.3e-06	3.6e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—CREBBP—urinary bladder cancer	5.24e-06	3.55e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—EGFR—urinary bladder cancer	5.23e-06	3.55e-05	CbGpPWpGaD
Vorinostat—NCOR1—Metabolism—EP300—urinary bladder cancer	5.23e-06	3.55e-05	CbGpPWpGaD
Vorinostat—HDAC2—Gene Expression—CREBBP—urinary bladder cancer	5.19e-06	3.52e-05	CbGpPWpGaD
Vorinostat—HDAC9—Disease—HRAS—urinary bladder cancer	5.18e-06	3.51e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—CCND1—urinary bladder cancer	5.17e-06	3.51e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—IGF1—urinary bladder cancer	5.17e-06	3.51e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—SRC—urinary bladder cancer	5.15e-06	3.5e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—CXCL8—urinary bladder cancer	5.1e-06	3.46e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—EP300—urinary bladder cancer	5.09e-06	3.46e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—KRAS—urinary bladder cancer	5.03e-06	3.41e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—MMP9—urinary bladder cancer	5.02e-06	3.41e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—CDKN1A—urinary bladder cancer	5e-06	3.39e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—PTEN—urinary bladder cancer	4.99e-06	3.39e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—SRC—urinary bladder cancer	4.95e-06	3.36e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—KRAS—urinary bladder cancer	4.94e-06	3.35e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—MYC—urinary bladder cancer	4.94e-06	3.35e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—NCOR1—urinary bladder cancer	4.9e-06	3.33e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—IL2—urinary bladder cancer	4.87e-06	3.31e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—TP53—urinary bladder cancer	4.86e-06	3.3e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—TP53—urinary bladder cancer	4.85e-06	3.29e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—EGFR—urinary bladder cancer	4.83e-06	3.28e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—CREBBP—urinary bladder cancer	4.82e-06	3.27e-05	CbGpPWpGaD
Vorinostat—HDAC1—Gene Expression—MYC—urinary bladder cancer	4.78e-06	3.24e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—EP300—urinary bladder cancer	4.76e-06	3.23e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—CCND1—urinary bladder cancer	4.75e-06	3.22e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—RHOA—urinary bladder cancer	4.74e-06	3.21e-05	CbGpPWpGaD
Vorinostat—HDAC3—Disease—HRAS—urinary bladder cancer	4.65e-06	3.16e-05	CbGpPWpGaD
Vorinostat—HDAC6—Signaling Pathways—HRAS—urinary bladder cancer	4.65e-06	3.15e-05	CbGpPWpGaD
Vorinostat—HDAC2—Hemostasis—HRAS—urinary bladder cancer	4.64e-06	3.15e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—SRC—urinary bladder cancer	4.63e-06	3.14e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—MYC—urinary bladder cancer	4.62e-06	3.13e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—MMP9—urinary bladder cancer	4.61e-06	3.13e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.6e-06	3.12e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—PTEN—urinary bladder cancer	4.59e-06	3.11e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—KRAS—urinary bladder cancer	4.56e-06	3.1e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—EGFR—urinary bladder cancer	4.52e-06	3.07e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—MYC—urinary bladder cancer	4.44e-06	3.01e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—TP53—urinary bladder cancer	4.39e-06	2.98e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—ERBB2—urinary bladder cancer	4.38e-06	2.98e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—EP300—urinary bladder cancer	4.37e-06	2.97e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—RHOA—urinary bladder cancer	4.36e-06	2.96e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—EGFR—urinary bladder cancer	4.34e-06	2.95e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—TERT—urinary bladder cancer	4.32e-06	2.93e-05	CbGpPWpGaD
Vorinostat—NCOR1—Disease—HRAS—urinary bladder cancer	4.27e-06	2.9e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—KRAS—urinary bladder cancer	4.27e-06	2.9e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—SRC—urinary bladder cancer	4.25e-06	2.89e-05	CbGpPWpGaD
Vorinostat—HDAC4—Signaling Pathways—HRAS—urinary bladder cancer	4.2e-06	2.85e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—CXCL8—urinary bladder cancer	4.16e-06	2.82e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—MYC—urinary bladder cancer	4.15e-06	2.81e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—KRAS—urinary bladder cancer	4.1e-06	2.78e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—EGFR—urinary bladder cancer	4.06e-06	2.75e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—TP53—urinary bladder cancer	4.05e-06	2.75e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—ERBB2—urinary bladder cancer	4.03e-06	2.74e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—IL2—urinary bladder cancer	3.97e-06	2.7e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—FGFR3—urinary bladder cancer	3.96e-06	2.69e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—PTGS2—urinary bladder cancer	3.94e-06	2.68e-05	CbGpPWpGaD
Vorinostat—HDAC8—Signaling Pathways—HRAS—urinary bladder cancer	3.88e-06	2.63e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—CCND1—urinary bladder cancer	3.87e-06	2.63e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—ESR1—urinary bladder cancer	3.85e-06	2.61e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—KRAS—urinary bladder cancer	3.83e-06	2.6e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—MYC—urinary bladder cancer	3.81e-06	2.59e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—TP53—urinary bladder cancer	3.79e-06	2.57e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—MMP9—urinary bladder cancer	3.76e-06	2.55e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—CDKN1A—urinary bladder cancer	3.75e-06	2.54e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—PTEN—urinary bladder cancer	3.74e-06	2.54e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—EGFR—urinary bladder cancer	3.73e-06	2.53e-05	CbGpPWpGaD
Vorinostat—HDAC9—Signaling Pathways—HRAS—urinary bladder cancer	3.63e-06	2.46e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—EP300—urinary bladder cancer	3.57e-06	2.42e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—KRAS—urinary bladder cancer	3.52e-06	2.39e-05	CbGpPWpGaD
Vorinostat—HDAC1—Disease—HRAS—urinary bladder cancer	3.48e-06	2.37e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—SRC—urinary bladder cancer	3.47e-06	2.35e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—CDKN1A—urinary bladder cancer	3.45e-06	2.34e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—PTEN—urinary bladder cancer	3.44e-06	2.34e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—TP53—urinary bladder cancer	3.41e-06	2.31e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CREBBP—urinary bladder cancer	3.37e-06	2.29e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—IGF1—urinary bladder cancer	3.33e-06	2.26e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—EP300—urinary bladder cancer	3.28e-06	2.23e-05	CbGpPWpGaD
Vorinostat—HDAC3—Signaling Pathways—HRAS—urinary bladder cancer	3.26e-06	2.21e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—SRC—urinary bladder cancer	3.19e-06	2.17e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—TP53—urinary bladder cancer	3.13e-06	2.12e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—MYC—urinary bladder cancer	3.11e-06	2.11e-05	CbGpPWpGaD
Vorinostat—HDAC2—Gene Expression—MYC—urinary bladder cancer	3.08e-06	2.09e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—RHOA—urinary bladder cancer	3.05e-06	2.07e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—EGFR—urinary bladder cancer	3.04e-06	2.06e-05	CbGpPWpGaD
Vorinostat—NCOR1—Signaling Pathways—HRAS—urinary bladder cancer	2.99e-06	2.03e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—KRAS—urinary bladder cancer	2.87e-06	1.95e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—MYC—urinary bladder cancer	2.86e-06	1.94e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—ERBB2—urinary bladder cancer	2.83e-06	1.92e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—EGFR—urinary bladder cancer	2.8e-06	1.9e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CXCL8—urinary bladder cancer	2.68e-06	1.82e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—KRAS—urinary bladder cancer	2.64e-06	1.79e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—IL2—urinary bladder cancer	2.56e-06	1.74e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—TP53—urinary bladder cancer	2.55e-06	1.73e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CCND1—urinary bladder cancer	2.5e-06	1.69e-05	CbGpPWpGaD
Vorinostat—HDAC1—Signaling Pathways—HRAS—urinary bladder cancer	2.44e-06	1.66e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—MMP9—urinary bladder cancer	2.42e-06	1.64e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—CDKN1A—urinary bladder cancer	2.41e-06	1.64e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—PTEN—urinary bladder cancer	2.41e-06	1.64e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—EP300—urinary bladder cancer	2.3e-06	1.56e-05	CbGpPWpGaD
Vorinostat—HDAC2—Disease—HRAS—urinary bladder cancer	2.25e-06	1.52e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—SRC—urinary bladder cancer	2.23e-06	1.52e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—MYC—urinary bladder cancer	2e-06	1.36e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—EGFR—urinary bladder cancer	1.96e-06	1.33e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—KRAS—urinary bladder cancer	1.85e-06	1.26e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—TP53—urinary bladder cancer	1.64e-06	1.12e-05	CbGpPWpGaD
Vorinostat—HDAC2—Signaling Pathways—HRAS—urinary bladder cancer	1.57e-06	1.07e-05	CbGpPWpGaD
